Q4 2024 Ascendis Pharma A/S Earnings Call Transcript

Feb 12, 2025 / 09:30 PM GMT

Release Date Price: MXN2614

Transcript

Key Points

Positve

Ascendis Pharma AS (ASND) achieved significant milestones in 2024, setting the stage for strong growth and value creation.
Skytrofa has established itself as a high-value growth hormone brand, capturing a 6.5% market share in the US.
Transcon PTH, the only FDA-approved treatment for hypoparathyroidism in adults, has launched in the US and is gaining traction as a new standard of care.
The company has a strong financial position with cash equivalents totaling €665 million, including a €100 million upfront payment from Novo Nordisk.
Ascendis Pharma AS (ASND) is expanding its TransCon technology platform beyond endocrine diseases, exploring opportunities in metabolic and cardiovascular diseases.

Negative

Revenue for Skytrofa in Q4 2024 was lower than the same period in 2023, despite volume growth.
The company faces challenges in establishing insurance reimbursement policies for new products like Yorvipa.
There is uncertainty regarding the timeline for insurance approvals, which are estimated to take 4 to 8 weeks.
Operating expenses increased by 3% in Q4 2024 compared to the previous year, driven by higher employee and commercial costs.
The company has not provided specific sales guidance for Yorvipa, creating uncertainty about future financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ASND.OQ - Ascendis Pharma A/S
Q4 2024 Ascendis Pharma A/S Earnings Call
Feb 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the 4th quarter and full year 2024 Ascendous farmer earnings conference call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.

To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Scott Smith, Chief Financial Officer. Please go ahead.

---------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.